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Objective To assess whether folic acid supplementation
ameliorates hot flushes.
Design Double-blind, placebo-controlled randomised trial.
Setting Nine hospitals in England.
Population Postmenopausal women experiencing ≥50 hot flushes
weekly.
Methods Women (n = 164) were randomly assigned in a 1:1 ratio
to receive folic acid 5 mg tablet or placebo daily for 12 weeks.
Participants recorded frequency and severity of hot flushes in a
Sloan Diary daily and completed Greene Climacteric and Utian
Quality of Life (UQoL) Scales at 4-week intervals.
Main outcome measures The change in daily Hot Flush Score at
week 12 from randomisation based on Sloan Diary Composite
Score B calculation.
Results Data of 143 (87%) women were available for the primary
outcome. The mean change (SD) in Hot Flush Score at week 12
was 6.98 (10.30) and 4.57 (9.46) for folic acid and placebo
group, respectively. The difference between groups in the mean
change was 2.41 (95% CI 5.68 to 0.87) (P = 0.149) and in the
adjusted mean change 2.61 (95% CI 5.72 to 0.49) (P = 0.098).
Analysis of secondary outcomes indicated an increased benefit in
the folic acid group regarding changes in total and emotional
UQoL scores at week 8 when compared with placebo. The
difference in the mean change from baseline was 5.22 (95% CI
1.16–9.28) and 1.88 (95% CI 0.23–3.52) for total and emotional
score, respectively.
Conclusions The study was not able to demonstrate that folic acid
had a statistically significant greater benefit in reducing Hot Flush
Score over 12 weeks in postmenopausal women when compared
with placebo.
Keywords Folic acid, hot flushes.
Tweetable abstract Folic acid may ameliorate hot flushes in
postmenopausal women but confirmation is required from a
larger study.
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Hot flushes are experienced by 75% of menopausal women
and half of them seek medical advice for severe symptoms.1
Since oestrogen deficiency is the cause, hormone replace-
ment therapy (HRT) is the first line therapy.2 However, the
publication of the Women Health Initiative trial in 20023
has dissuaded women from taking HRT due to concerns
over potential adverse effects.4,5 Furthermore, the use of
HRT in breast cancer survivors is not recommended for
fear of recurrence, and the management of vasomotor
symptoms in these women has become a pressing clinical
challenge due to improved survival rates such that good
quality of life has become a benchmark for successful ther-
apy.6,7 The increased use of aromatase inhibitors leading to
profound oestrogen deprivation8 and the limited relief
achieved by the currently available non-hormonal reme-
dies9 have made it necessary to search for a new effective
and safe therapy.
Hot flushes are triggered by instability in the thermoreg-
ulatory centre within the hypothalamus or the vasomotor
centres in the medulla due to increased central noradrener-
gic activity.10,11 In addition, the reduction in oestrogen
activity increases the expression of 5-HT2A receptors, lead-
ing to lowered threshold to internal or external stimuli and
resulting in peripheral vasodilation.12 Oestrogen therapy
regulates monoamine neurotransmitters in the brain, nora-
drenaline and serotonin, which are the basis of its ability to
prevent hot flushes. It was found significantly to decrease
plasma noradrenaline, increase plasma serotonin13 and aug-
ment serotonergic activity14 in postmenopausal women.
Folic acid is involved, via donation of a methyl group, in
the synthesis of monoamine neurotransmitters.15 Studies
have reported that it reduced noradrenaline secretion16,17
and increased serotonin activity.16,18 In rodents treated
with folic acid, an antidepressant effect was observed
through the regulation of the noradrenergic receptors (a1
and a2) and serotonergic receptors (5-HT1A and 5-HT2A/
2C).
16 Four small studies19–22 have reported that folic acid
ameliorates hot flushes in postmenopausal women; how-
ever, these studies had substantial methodological flaws.
We hypothesised that folic acid supplementation amelio-
rates hot flushes by the same mechanism as oestrogen
replacement, i.e. by interacting with monoamine neuro-
transmitters in the brain, lowering noradrenaline and
increases serotonin activities.23 The present randomised
controlled trial (RCT) was designed to assess the efficacy of
folic acid supplementation versus placebo to symptomatic
postmenopausal women in terms of amelioration of hot
flushes as the primary outcome measure, and to assess the
efficacy on other menopausal symptoms and Quality of life
(QoL) as secondary outcome measures.
Methods
Study oversight
The trial is titled the Phase III randomised study of FOlic
Acid supplementation in the management of Menopausal
symptoms in cancer survivors and healthy postmenopausal
women (FOAM Trial). It was co-sponsored by Sandwell
and West Birmingham Hospitals NHS Trust and University
of Birmingham, and was conducted under the auspices of
the Cancer Research UK Clinical Trial Unit (CRCTU Ref
No.: MX3009). The trial was funded by a grant from
‘Research for Patient Benefit‘, Ref: PB-PG-1111-26094.
Guys’ and St Thomas’ Hospital Pharmacy Manufacturing
Unit was responsible for purchasing the trial drug from
Actavis (Devon, UK, rebranded as Accord Healthcare in
January 2017), and for manufacturing the placebo tablets.
Study oversight and monitoring were provided by a trial
steering committee and by an independent data and safety
monitoring committee. The trial protocol and ethical
approval are available on request.
Study participants
The participants were recruited from nine hospitals across
the UK via menopause, oncology or research clinics.
Women were eligible for enrolment in the study if they
were 40–70 years of age, with normal baseline serum folate
level (3.1–20.0 µg/l), postmenopausal (either healthy, or
breast or endometrial cancer survivors with iatrogenic
onset of menopause) and experiencing ≥50 hot flushes per
week as quantified from daily Sloan Diary24 recordings for
7 days prior to randomisation. Menopausal status was
defined as cessation of menstruation for 12 months or
6 weeks after surgical removal of ovaries. All participants
provided written informed consent.
Participants were excluded from randomisation in the
following circumstances: (1) baseline serum folic acid level
above the normal laboratory range; (2) intestinal malab-
sorption, e.g. coeliac or Crohn’s disease; (3) chronic renal
impairment; (4) chronic conditions mimicking climacteric
presentation, e.g. poorly controlled hypertension, hypergly-
caemia or thyroid instability; (5) pernicious anaemia due
to vitamin B12 deficiency; (6) alcohol consumption >14
units per week; (7) phaeochromocytoma or carcinoid syn-
drome; (8) allergy to folic acid; taking prohibited medica-
tions unless the participant was willing and it was safe to
discontinue doing so. In such cases, wash out periods were
allowed before randomisation and were estimated based on
the drug specifications published on MHRA website.25
Study design and drug regimen
Participants were randomly assigned in a 1:1 ratio to
receive tablets containing either folic acid 5 mg or matched
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placebo to be taken orally once a day from the time of ran-
domisation for 12 completed weeks. The appearance of the
study medications was identical so that participants and
researchers were unaware of the study group assignments
throughout the trial. Randomisation was performed cen-
trally in a double-blinded manner via telephone to
CRCTU, which allocated treatments using a computer min-
imisation technique with a random element that was devel-
oped by CRCTU. Randomisation was stratified by
participant subgroup: healthy women versus breast or
endometrial cancer survivors and body mass index (BMI)
≤30 versus >30. Participants were required to record the
frequency and severity of hot flushes on a daily basis in a
Sloan Diary24 over 12 weeks while taking the study medica-
tions. Participants were also requested to complete the
Greene Climacteric Scale26–28 and Utian QoL Scale29 at
entry and at weeks 4, 8 and 12. Blood samples were
obtained for serum folate at trial entry and week 12.
Outcome measures
The primary outcome measure was the change in daily Hot
Flush Score at 12 weeks from randomisation based on the
validated composite score B calculation24. This was calcu-
lated based on frequency and severity as recorded by par-
ticipants in Sloan Diaries. The secondary outcome
measures were the changes at weeks 4, 8 and 12 from ran-
domisation in the following: (1) hot flushes frequency as
calculated using the frequency score B, (2) hot flushes
severity as calculated using the severity score B, (3) occur-
rence of a response (defined as a reduction in Hot Flush
Score of ≥50%) as calculated using composite score B, (4)
other menopausal symptoms as measured by the Greene
Climacteric Scale, (5) longitudinal QoL data as measured
by the Utian QoL Scale. The trial investigated the treatment
effect on outcomes in specific prognostic subgroups of
healthy women versus breast or endometrial cancer sur-
vivors and BMI ≤30 versus >30. Data on planned explora-
tory translational outcomes were not generated for
logistical reasons in relation to the Covid-19 pandemic.
Statistical analysis
Sample size calculation
The null hypothesis being tested was that there is no differ-
ence in the mean change in composite score B at 12 weeks
between the two treatment groups. Previous literature of
375 breast cancer women randomised to placebo reported
a mean Hot Flush Score at randomisation of 15.7
(SD = 11.7). A 3.6-point reduction (~25%) in score was
reported and was expected in women randomised to pla-
cebo. The standard deviation of the change from baseline
was reported as 7.1. A clinically relevant reduction is an
additional ≥20% reduction with folic acid over and above
the placebo effect, which translates to ≥7-point reduction
(~45%) in Hot Flush Score at 12 weeks. To detect a true
3.4-point mean difference in the change in Hot Flush Score
with folic acid compared with placebo using a two-sided
type 1 error a = 0.05 and 80% power and a within-group
standard deviation of 7.1 for the change from baseline,
70 patients are required per arm, i.e. 140 in total. We
planned to include 162 women in the study to account for
a 15% rate of loss to follow-up.
Analysis
All outcome measures were recorded longitudinally at
screening, 4, 8 and 12 weeks. The analysis used an intention-
to-treat type approach in which all women were included
regardless of their compliance with treatment. The primary
analysis compared the treatment groups in terms of the pri-
mary outcome measure, change in daily Hot Flush Score at
12 weeks from randomisation, using a two-sample t-test
with a significance level of P < 0.05. The primary outcome
measure was analysed using a linear regression model, which
evaluated treatment effects adjusted by clinically relevant
baseline covariates (number of hot flushes at screening and
folate level at baseline) and stratification factors (healthy ver-
sus cancer as categorical and BMI as continuous). All out-
comes were analysed using multi-level mixed effects models,
where repeated measurements from baseline through to
12 weeks were analysed as random effects, and clinically rele-
vant baseline covariates and stratification factors were forced
into the model as fixed effects. Where the shape of the data
appeared to be quadratic over time (week), time was used as
a quadratic term in the model. The mean change in serum
folate at week 12 from baseline was compared between the
groups using a two-sample t-test. P-values for all secondary
outcomes were included as indicators of the strength of evi-
dence, not for decision-making.
A planned sensitivity analysis was performed which
accounted for missing data via multiple imputation for the
primary outcome analysis. For week 1 to be included,
women were required to have data available. This analysis
was performed using a regression-based imputation model
using a bootstrap approach. For women with complete data
up to a particular week, a multiple regression model was
developed that included the outcome at that visit as the
dependent variable and outcomes at previous visits, treat-
ment, site and stratification variables as independent vari-
ables. Models were constructed separately for subsequent
visits. Missing value was imputed sequentially starting from
week 2 to week 12. This was repeated 100 times, resulting
in 100 complete analysis datasets. The analyses were per-
formed separately and then combined into one inference.30
A sensitivity analysis using the Last Observation Carried
Forward (LOCF) imputation procedure was also per-
formed, which used the last observed value for a
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participant to fill in missing values. The sensitivity analyses
were unadjusted and adjusted as described above. STATA
v16.0 (StataCorp LLC, College Station, TX, USA) was used
for the analysis.
Patient involvement
Patient and public involvement in the study was minimal.
It was limited to input into the funding application and
occasional Steering Committee Meeting attendance. This
was a reflection of the time when the study was designed
and planned in year 2012.
Results
A total of 1493 women were screened for eligibility from 9
July 2015 through 30 April 2019, and 164 of these women
were randomly assigned to receive either folic acid 5 mg
tablets (n = 83) or placebo (n = 81). As women were
allowed self-referral, and given the strict inclusion and exclu-
sion criteria, a high number of screened women (89%) were
deemed ineligible for randomisation. For 105 (67%) ran-
domised women, full compliance with the 12 weeks of allo-
cated treatment was recorded, with only 13 (8%) women
receiving no treatment; compliance was balanced across
treatment arms (Figure 1). The percentage of women with
available data for the primary outcome was 87% (143; 74 in
the folic acid group and 69 in the placebo group). The char-
acteristics of the participants at baseline were similar in the
two groups (Table 1). The compliance data were collected at
weeks 4, 8 and 12 and are presented in Table 2.
Primary outcome
The mean Composite Hot Flush Score B decreased over
time in both groups and the mean change (SD) at week 12
was 6.98 (10.30) and 4.57 (9.46) for the folic acid and
placebo group, respectively. The difference in the mean
change between groups was 2.41 (95% CI 5.68 to 0.87)
with t-test giving P = 0.149. From the adjusted linear
regression model, the difference in the mean change was
2.61 (95% CI 5.72 to 0.49) with P = 0.098. There was
no statistically significant difference between the two
groups at other time points (Figure 2, Table S1). Explora-
tory subgroup analysis gave some indication of a more pro-
nounced benefit in women with BMI ≤30 (Figure S4).
Secondary outcomes
There was no statistically significant difference for severity
score B, frequency score B or the number of responders at
any time point (Figure S1, Table S1). A lower score for the
Greene Climacteric Scale represents an improvement in
symptoms. The scores were similar for both groups and no
statistically significant difference was found at any time point
for any subscale score. A higher score equates to better QoL
for the Utian QoL Score. The scores were similar for both
groups and no statistically significant difference was found at
any time point for any subscale score with the exception of
the total score and emotional score at week 8. The mean
changes from baseline in total score and emotional score
were statistically significantly higher for the folic acid group
than for the placebo group. A total of 151 women had data
available for the total score and emotional score at trial entry
and week 8: 77 in the folic acid group and 74 in the placebo
group. The mean change (SD) from baseline in total score
was 0.88 (12.54) and 4.34 (12.69) for the folic acid group
and the placebo group, respectively. The difference in the
mean change was 5.22 (95% CI 1.16–9.28). The mean change
(SD) for emotional score from baseline was 1.34 (5.11) and
0.54 (5.12) for the folic acid group and placebo group,
respectively. The difference in the mean change was 1.88
(95% CI 0.23–3.52). The overall climacteric symptoms and
QoL analysis are presented in Figure 2. Detailed analysis for
all domains at various time points are presented in Fig-
ures S2 and S3 and Table S2. None of the primary or sec-
ondary outcomes provided a statistically significant result
when analysed using multilevel mixed-effects modelling
(Tables S3 and S4).
The mean change ( SD) in serum folate at week 12
was significantly higher in the folic acid group
(11.06  3.86) than in the placebo group (0.66  3.15);
the difference in the mean change was 10.39 (95% CI 9.18–
11.61) with P < 0.001 (Table S5).
As there were no data for the primary outcome analysis
for 21 women, a sensitivity analysis was performed. It was
possible to impute data for a further 15 women, thus
increasing the total number to 158. The mean change (SD)
in Hot Flush Score at week 12 was 6.79 (10.21) and
4.09 (9.82) for the folic acid and the placebo group,
respectively. The difference in the unadjusted mean change
was 2.69 (95% CI 5.88 to 0.50) with P = 0.099. The
difference in the adjusted mean change was 2.82 (95% CI
5.87 to 0.24) with P = 0.071. The sensitivity analysis was
repeated using the LOCF procedure, which displayed simi-
lar results (Table S6).
The frequency of adverse events was similar in the two
treatment groups. In total, 43 adverse events were observed
in 20 women: 22 in 12 women on folic acid and 21 in eight
women on placebo. All events resolved spontaneously. The
causality of the treatment with these adverse events is hard
to ascertain but was considered unlikely to be related.
Details of events and grades are provided in Table S7.
Discussion
Main findings
This RCT was not able to demonstrate that folic acid had a
statistically significant greater benefit in reducing Hot Flush
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Score over 12 weeks in postmenopausal women when com-
pared with placebo. This may be due to a higher than
expected response to placebo. There was no statistically
significant difference in the secondary outcome measures
except in the total and emotional Utian QoL scores at week
8, where a significant improvement was found in the folic
74 analysed for the primary outcome measure 
83 analysed for all secondary outcome measures 
9 did not complete the 12 
week assessment 
83 allocated to receive folic acid 5 mg 
82 received allocated treatment 
1 withdrew before start of treatment 
12 did not complete the 12 
week assessment 
81 allocated to receive placebo 
80 received allocated treatment 
1 withdrew before start of treatment 
69 analysed for the primary outcome measure 
81 analysed for all secondary outcome measures 
164 randomised 
1493 assessed for eligibility 
1329 excluded (89%): 
-Concomitant medicaons: 426 (32%)† 
-Declined: 292 (22%) 
-Hot flushes frequency <50 per week: 155 (12%) 
-Last period <12 months: 134 (10%) 
-Smoking: 37 (3%) 
-Contraindicaon e.g. Crohn’s disease: 15 (1%) 
-Others e.g. no reason documented, age >70years, 
previous folic acid intolerance, did not consent: 270 (20%) 
 
11 disconnued treatment due to: 
- Toxicity (n=1) 
- Withdrew consent (n=3) 
- Toxicity + Withdrew consent (n=1) 
- Other (n=6) 
10 disconnued treatment due to: 
- Toxicity (n=3) 
- Withdrew consent (n=2) 
- Toxicity + withdrew consent (n=1) 
- Other (n=4) 
Figure 1. Trial profile. †Concomitant medications breakdown (n = 426): HRT: 238 (56%), Serotonin reuptake inhibitors 48 (11%), LNG-IUS or
oestrogen implant: 32 (8%), Tamoxifen: 27 (6%), None steroidal anti-inflammatory: 15 (34%), Herbal remedies: 9 (2%), Folic acid: 6 (1%), Others
50 (12%).
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acid group. However; this difference disappeared at week
12. This finding was not replicated in a multilevel mixed-
effects model analysis.
Strengths and limitations
This is the first well-designed trial robustly investigating
the hypothesis that folic acid can ameliorate hot flushes in
postmenopausal women. The standard therapeutic dose of
5 mg was used. The study screening criteria were precise
and ensured that a carefully characterised group of women
with normal folate levels were included. Randomisation
and study conduct were according to a protocol using
double-blinding methods of concealment and computerised
randomisation. The drop-out rate was lower than expected
and the study included a modified intention-to-treat sensi-
tivity analysis.
The trial demonstrated that folic acid was safe and well-
tolerated, which is consistent with previous reports showing
that a daily supplement of up to 10 mg folic acid rarely
caused side effects in healthy individuals.31,32 A meta-
analysis, including 13 RCTs with 49 621 participants that
compared folic acid with placebo, found no change in
overall or site-specific cancer incidence when folic acid sup-
plementation was used at doses higher than those for forti-
fication for an average duration of 5.2 years.33
We acknowledge that no formal measures were taken to
address the issue of multiple testing in the secondary out-
come measures but intend these to be used only as indica-
tors of the strength of evidence. A limitation of this study
is that due to slow recruitment, the power was reduced to
reduce the required sample size. The sample size used in
the study assumed a within-group standard deviation of
7.1 for the change from baseline, but we observed greater
variability with a standard deviation greater than this in
both treatment groups. This, combined with observing a
smaller difference than anticipated, has resulted in the
study being underpowered to detect the clinically relevant
difference specified in the design. The planned sensitivity
analysis increased the patient population for the primary
outcome by a further 15 women. As a result, the analysis
showed a trend towards a statistically significant result for
the unadjusted (P = 0.099) and adjusted (P = 0.071) analy-
ses. The overall treatment effect over time from the multi-
level mixed-effects model was not statistically significant
(P = 0.614).
We also considered the treatment effect in women with
a high frequency of hot flushes at baseline using a cut-off
of 72, which is the median number of hot flushes. The
treatment effect was 4.62 (95% CI, 10.66 to 1.42) and
0.50 (95% CI, 3.20 to 2.21) in the >72 group and ≤72
group, respectively.
The major limitation in this study was the higher than
expected placebo response, which surpassed previously
recorded responses in this field. The question that
remained unanswered was whether a larger population size
might have shown a statistically significant difference or
that folic acid supplementation might not be superior to
placebo.
Interpretation
It was plausible to hypothesise that folic acid ameliorates
hot flushes in postmenopausal women. Tetrahydrofolates,
the metabolically active forms of folic acid, are essential
for the biosynthesis of serotonin and noradrenaline.
5-Methyltetrahydrofolate participates in re-methylation of
the amino acid metabolite homocysteine, creating








Mean  SD 55.4  5.1 56.2  5.9 55.8  5.5
Patient subgroups, n (%)
Healthy woman 67 (81) 66 (82) 133 (81)
Breast cancer survivor 14 (17) 14 (17) 28 (17)
Endometrial cancer survivor 2 (2) 1 (1) 3 (2)
Body mass index, n (%)
≤30 64 (77) 63 (78) 127 (77)
>30 19 (23) 18 (22) 37 (23)
Number of hot flushes at screening
Mean  SD 85  37 85  51 85  44
Baseline folate level (µg/l)
Mean  SD 7.8  3.1 7.6  3.1 7.7  3.1
SD, standard deviation.








0% 6 (7) 7 (8) 13 (8)
33% 11 (13) 12 (15) 23 (14)
67% 11 (13) 12 (15) 23 (14)
100% 55 (67) 50 (62) 105 (64)
Note Compliance data was collected at week 4, 8 and 12.
100% – women were compliant throughout the trial.
67% – women were compliant for two-thirds of the treatment
period.
33% – women were compliant for one-third of the treatment
period.
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methionine. S-adenosylmethionine, the methionine
metabolite, acts as a methyl donor allowing both the sero-
tonin and catecholamine pathways to function properly.
5-Methyltetrahydrofolate has also been shown to augment
production of tetrahydrobiopterin, which is an essential
nutrient cofactor in the biosynthesis of serotonin and
noradrenaline.15,34–37 Moreover, folate deficiency has been
associated with reduced serotonin activity,38 and folic
acid supplementation increased serotonin metabolite level
in the cerebrospinal fluid of patients suffering from
depression.18
Four small studies suggested that folic acid supplementa-
tion significantly ameliorated hot flushes in post-
menopausal women. The first study, which included two
groups (n = 23 each), reported significant improvement of
hot flushes and lowering in the brain noradrenaline end
metabolite with daily folic acid 5 mg supplementation for
4 weeks when compared with placebo.19 The second study,
which included two groups (n = 20 each), demonstrated
an average 57% reduction in the frequency in hot flushes
with daily folic acid 5 mg supplementation for 4 weeks
when compared with no treatment.20 The third study,
which included two groups (n = 35 each), revealed signifi-
cant improvement in severity, duration and frequency of
hot flushes with daily folic acid 1 mg supplementation for
4 weeks as well as with placebo tablets, with more
improvement in the folic acid group.21 The fourth study
included three groups (n = 40 each) respectively taking a
daily supplement of folic acid 1 mg, Omega-3 1000 mg or
placebo tablets for 12 weeks. There was a statistically signif-
icant improvement in severity, duration and frequency of
hot flushes in the folic acid group when compared with
placebo.22 However, all these studies had serious method-
ological flaws. First, they were underpowered with small
sample size. Secondly, folic acid supplementation was given
for a short duration of 4 weeks, raising the suspicion of a
placebo effect. Thirdly, bias in allocation and assessment
cannot be excluded given the poor reporting of the meth-
ods. In one study, placebo was not used for comparison. In
all studies, women were allocated by alternation into the
Figure 2. Comparison between the treatment groups in the mean change in hot flushes, menopausal symptoms and quality of life over time from
randomisation to week 12. A = Composite Score B; B = Total Score of Greene Climacteric Scale; C = Total Score of Utian Quality of Life Scale.
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groups. Fourthly, two studies used a small dose of 1 mg of
folic acid and reported positive results. Last, no validated
method to assess the frequency and intensity of the flushes
was used, and the improvement was subjectively described
by women based on overall feelings.
Conclusion
This RCT was not able to demonstrate that folic acid had a
statistically significant greater benefit in reducing Hot Flush
Score over 12 weeks in postmenopausal women when com-
pared with placebo. This may be due to a higher than
expected response to placebo. Definitive evidence of benefit
would require a larger study.
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